La Jolla Pharmaceutical Co LJPC:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 03/02/21 EST
5.06UNCH (UNCH)
Volume
3,039
Close
5.06quote price arrow down-0.05 (-0.98%)
Volume
148,311
52 week range
3.36 - 8.10

...

Loading . . .

KEY STATS

  • Open5.12
  • Day High5.21
  • Day Low5.05
  • Prev Close5.06
  • 52 Week High8.10
  • 52 Week High Date05/07/20
  • 52 Week Low3.36
  • 52 Week Low Date10/30/20
  • Market Cap138.54M
  • Shares Out27.38M
  • 10 Day Average Volume0.33M
  • Dividend-
  • Dividend Yield-
  • Beta2.46
  • 1 Year % Change-23.68

RATIOS/PROFITABILITY

  • EPS (TTM)-2.25
  • P/E (TTM)-2.25
  • Fwd P/E (NTM)-11.00
  • EBITDA (MRQ)-53.996M
  • ROE (MRQ)-933.89%
  • Revenue (MRQ)29.72M
  • Gross Margin (MRQ)83.85%
  • Net Margin (MRQ)-205.85%
  • Debt To Equity (MRQ)-0.00%

EVENTS

  • Earnings Date05/07/2021
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest La Jolla Pharmaceutical Co News

There is no recent news for this security.

Latest LJPC News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
La Jolla Pharmaceutical Company is focused on development and commercialization of therapies for patients suffering from life-threatening diseases. The Company’s products include GIAPREZA, XERAVA, LJPC-0118 and LJPC-401. The GIAPREZA (angiotensin II) is a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shock. The XERAVA...
Kevin Tang
Chairman
Larry Edwards
President
Michael Hearne CPA
Chief Financial Officer
Address
4747 EXECUTIVE DRIVE, SUITE 240
San Diego, CA
92121
United States